MedTrace Logo

Drug Discovery for Parkinson's With Mutations in the GBA Gene

NCT05536388 · Status: RECRUITING · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2025-03-03

No results posted yet for this study

Summary

The New York Stem Cell Foundation (NYSCF) Research Institute is performing this research to accelerate Parkinson's disease research and drug development by using cells from the body (such as skin or blood cells) to make stem cells and other types of cells, conduct research on the samples, perform genetic testing, and/or store the samples for future use.

Through this research, researchers hope to identify future treatments or even cures for Parkinson's disease.

Conditions

  • Parkinson Disease
  • Gaucher Disease
  • Healthy
  • GBA Gene Mutation

Interventions

OTHER

Biological Sample Collection

Skin biopsy (2-3mm) and/or blood (up to 50 mL); saliva; excess/leftover biospecimens that were (or will be) collected for other purposes (e.g., medical procedure)

Sponsors & Collaborators

  • Silverstein Foundation

    collaborator UNKNOWN

  • New York Stem Cell Foundation Research Institute

    lead OTHER

Principal Investigators

  • Laura Andres-Martin · New York Stem Cell Foundation Research Institute

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2022-07-15
Primary Completion
2025-07-15
Completion
2025-07-15

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05536388 on ClinicalTrials.gov